CD47 Assay Portfolio Service
Creative Biolabs offers a specialized CD47 assay service to advance targeted cancer therapy and diagnosis. CD47, a protein often overexpressed on cancer cells, acts as a "don't eat me" signal to block phagocytosis by macrophages. Our service utilizes advanced technology and expertise to precisely analyze CD47 expression levels and its functional status. By providing crucial insights into this immune checkpoint, we help clients develop and validate novel therapeutics, such as CD47-blocking antibodies, to effectively unlock the immune system's ability to attack tumors.
Background What We Can Offer Publication Why Choose Us FAQs Customer Review Related Services Contact Us
Unlocking the 'Don't Eat Me' Signal
CD47 is a 50 kDa cell surface protein, expressed on nearly all body cells, including erythrocytes. Belonging to the immunoglobulin family, its primary ligand is SIRPα, found on myeloid cells. Their binding transmits a crucial "don't eat me" signal that inhibits phagocytosis by macrophages. When CD47 expression is reduced, this signal weakens, allowing macrophages to engulf these cells. The CD47-ligand axis is also essential for various other physiological processes, including neutrophil chemotaxis, nervous system development, and regulating immune tolerance and T-cell activation.
Fig.1 The therapeutic landscape of CD47-SIRα targeting in hematologic malignancies. 1, 3
Creative Biolabs' Comprehensive CD47 Assay Portfolio Service
Creative Biolabs offers a robust, integrated suite of services to support every stage of CD47-targeted drug development. Our portfolio is built on a foundation of scientific rigor, state-of-the-art technology, and extensive experience.
Contact us today to discuss your project and discover how our CD47 assay portfolio service can advance your research and unlock the next breakthrough in immuno-oncology.
Publication
This review explores targeting the CD47-SIRPα axis for cancer therapy. CD47, overexpressed on tumors, binds SIRPα on macrophages, delivering a "don't eat me" signal to evade immune clearance. Blocking this interaction promotes phagocytosis, stimulates adaptive immunity, and directly kills cancer cells. The article covers the pathway's biology, therapeutic agents in development, and clinical challenges like on-target anemia, concluding that it is a promising yet complex strategy requiring further optimization to improve efficacy and safety.
Fig.2 Targeting the CD47-SIRPα axis for cancer therapy. 2, 3
Why Choose Us?
Our commitment to scientific excellence and our comprehensive, integrated platform make Creative Biolabs the ideal partner for your CD47-targeted research. We offer a depth of expertise that allows us to navigate the unique challenges of this pathway, providing reliable data and strategic guidance. Our experience is evidenced by a proven track record in advancing preclinical programs. Published data from our collaborations demonstrate a high success rate in identifying and validating potent therapeutic candidates.
Discover How We Can Help - Request a Consultation
FAQs
Q1: Why is targeting CD47 so challenging?
A1: Targeting CD47 is challenging because it is expressed on nearly all normal cells, including red blood cells. Blocking CD47 on these cells can lead to unwanted side effects like anemia.
Q2: Can you test my antibody in combination with other drugs
A2: Absolutely. Our portfolio is highly customizable. We can design assays to evaluate the synergistic potential of your CD47-targeting agent in combination with other immunotherapies or chemotherapeutic drugs.
Q3: How do your phagocytosis assays differ from others
A3: Our phagocytosis assays are the gold standard for CD47 blockade. We use primary macrophages and advanced flow cytometry to provide precise, quantitative data on the rate of tumor cell engulfment. We also offer live-cell imaging to provide a visual and dynamic record of the process.
Customer Review
-
Exceptional Phagocytosis Assays
Creative Biolabs' standardized protocols and rigorous controls provide data we can trust. I especially appreciate the detailed flow cytometry readouts, which are essential for our research. - J. S*****y
-
Addressing Off-Target Effects
Creative Biolabs' expertise in navigating the off-target effects of CD47-targeting agents was invaluable. They helped us design specific assays to monitor potential side effects on normal blood cells, which gave us critical data for our safety profile. - L. P*****r
Related Services
To fully leverage the potential of CD47-targeted therapy, you may also benefit from our other services.
Targeted Protein Degradation Service
Targeted protein degradation is a new drug discovery approach that completely removes proteins by using the cell's natural systems, offering a way to target previously undruggable proteins and overcome drug resistance.
Learn More →
DCs-Involved Immuno-Oncology Models for In Vivo Testing
Creative Biolabs has created DC-involved immuno-oncology models for in vivo antitumor efficacy testing. These models, which can be custom-developed, are used for preclinical evaluation of anti-cancer drugs and immunotherapies.
Learn More →
Contact Us
The successful development of a CD47-targeted therapy requires a partner with deep scientific expertise and a comprehensive assay platform. Creative Biolabs is uniquely positioned to guide your research from initial binding characterization through to comprehensive in vivo proof-of-concept studies. We are dedicated to providing the solutions you need to accelerate your journey toward clinical success.
To learn more about our services or to discuss your specific project, please reach out to our team of experts.
References
-
Yang, Hua, Yang Xun, and Hua You. "The landscape overview of CD47-based immunotherapy for hematological malignancies." Biomarker Research 11.1 (2023): 15. https://doi.org/10.1186/s40364-023-00456-x
-
Zhang, Wenting, et al. "Advances in anti-tumor treatments targeting the CD47/SIRPα axis." Frontiers in immunology 11 (2020): 18. https://doi.org/10.3389/fimmu.2020.00018
-
Distributed under Open Access license CC BY 4.0, without modification.
